Wegovy, Ozempic (wskazany w leczeniu cukrzycy), dulaglutyd (raz w tygodniu), np
It is often prescribed off-label (for a non-FDA-approved use) for weight loss
Conclusion Four completed trials now confirm retatrutide's efficacy across different populations, doses, and durations: Phase 2 (338 patients, 48 weeks): 24.2% proof of concept TRIUMPH-4 (445 patients, 68 weeks): 28.7% first Phase 3 confirmation TRIUMPH-1 (2,339 patients, 80 weeks): 28.3% pivotal confirmation in general obesity population TRIUMPH-1 extension (subset, 104 weeks): 30.3% weight loss continues beyond 80 weeks TRANSCEND-T2D-1 (537 patients, 40 weeks): 16.8% weight loss and -2.0% HbA1c in type 2 diabetes The consistency between TRIUMPH-4 (28.7%) and TRIUMPH-1 (28.3%) across two very different populations is the most important finding for obesity it means the results aren't driven by population-specific factors, they reflect the drug's fundamental mechanism
Additionally, some studies suggest that L-Carnitine could contribute to overall well-being by reducing oxidative stress and inflammation, which are associated with various chronic health conditions
Ozempic is $1,350/month
